NCT03370276 2026-03-10
Cetuximab & Nivolumab in Patients With Recurrent/Metastatic Head & Neck Squamous Cell Carcinoma
H. Lee Moffitt Cancer Center and Research Institute
Phase 1/2 Completed
Clinical Trials
43 trialsNCT05002270 2026-01-13
JAB-21822 Activity in Adult Patients With Advanced Solid Tumors Harboring KRAS G12C Mutation
Jacobio Pharmaceuticals Co., Ltd.
Phase 1/2 Completed
NCT04349267 2025-12-17
Study of BMS-986315 Alone and in Combination With Nivolumab or Cetuximab in Participants With Advanced Solid Tumors
Bristol-Myers Squibb
Phase 1/2 Completed
NCT05756153 2025-08-12
A Study of GFH925 in Combination With Cetuximab in Previously Untreated Advanced NSCLC Harboring KRAS G12C Mutation
Genfleet Therapeutics (Shanghai) Inc.
Phase 1/2 Completed
NCT04616196 2025-06-08
Study of NKTR 255 in Combination With Cetuximab in Solid Tumors
Nektar Therapeutics
Phase 1/2 Completed
NCT04495621 2025-05-01
C-PRECISE-01
Menarini Group
Phase 1/2 Completed
NCT03428958 2025-04-23
A Safety, Pharmacokinetic and Efficacy Study of NUC-3373 in Combination With Standard Agents Used in Colorectal Cancer Treatment
NuCana plc
Phase 1/2 Completed
NCT00545545 2025-03-19
Safety/Efficacy Study of Imprime PGG With Cetuximab in Patients With Recurrent/Progressive Colorectal Carcinoma
HiberCell, Inc.
Phase 1/2 Completed
NCT03693612 2024-08-28
GSK3359609 Plus Tremelimumab for the Treatment of Advanced Solid Tumors
GlaxoSmithKline
Phase 1/2 Completed
NCT02101034 2023-12-21
PD 0332991 and Cetuximab in Patients With Incurable SCCHN
Washington University School of Medicine
Phase 1/2 Completed
NCT02599324 2023-11-18
Study to Evaluate Ibrutinib Combination Therapy in Patients With Selected Gastrointestinal and Genitourinary Tumors
Pharmacyclics LLC.
Phase 1/2 Completed
NCT01004731 2023-05-25
Study of Anti-Epidermal Growth Factor Receptor (EGFr) Antibody, Cetuximab, in Combination With Gemcitabine/Carboplatin in Patients With Stage IV Lung Cancer
University of Alabama at Birmingham
Phase 1/2 Completed
NCT02643550 2023-05-12
Study of Monalizumab and Cetuximab in Patients With Recurrent or Metastatic Squamous Cell Carcinoma of the Head and Neck
Innate Pharma
Phase 1/2 Completed
NCT04790448 2023-02-15
Efficacy of VIC Regimen in BRAF Mutant Metastatic Colorectal Cancer
Sun Yat-sen University
Phase 1/2 Completed
NCT02713373 2022-10-06
Cetuximab and Pembrolizumab in Treating Patients With Colorectal Cancer That is Metastatic or Cannot Be Removed by Surgery
Roswell Park Cancer Institute
Phase 1/2 Completed
NCT01332266 2022-01-03
E7050 in Combination With Cetuximab Versus Cetuximab Alone in the Treatment of Platinum-Resistant Squamous Cell Carcinoma of the Head and Neck
Eisai Inc.
Phase 1/2 Completed
NCT00660218 2021-11-08
A Phase I/II Study of Radiation Therapy, Paclitaxel Poliglumex and Cetuximab in Advanced Head and Neck Cancer
State University of New York - Upstate Medical University
Phase 1/2 Completed
NCT01077986 2021-04-21
Everolimus, Cetuximab and Capecitabine in Patients With Metastatic Pancreatic Cancer
Academisch Medisch Centrum - Universiteit van Amsterdam (AMC-UvA)
Phase 1/2 Completed
NCT01075048 2021-04-08
ARQ 197 in Combination With Chemotherapy in Patients With Metastatic Colorectal Cancer
Daiichi Sankyo
Phase 1/2 Completed
NCT02953782 2021-03-01
Study of Magrolimab (Hu5F9-G4) in Combination With Cetuximab in Participants With Solid Tumors and Advanced Colorectal Cancer
Gilead Sciences
Phase 1/2 Completed
NCT00851877 2020-08-21
Nab-Paclitaxel, Cisplatin, and Cetuximab With Concurrent Radiation Therapy for Locally Advanced Head and Neck Cancer
University of Texas Southwestern Medical Center
Phase 1/2 Completed
NCT02845856 2019-09-12
Combination of Cetuximab and NK Immunotherapy for Recurrent Non-small Cell Lung Cancer
Fuda Cancer Hospital, Guangzhou
Phase 1/2 Completed
NCT00923299 2019-04-16
THERAPY
Institut du Cancer de Montpellier - Val d'Aurelle
Phase 1/2 Completed
NCT01252628 2018-05-16
Phase 1 and 2 Study of PX-866 and Cetuximab
Seagen Inc.
Phase 1/2 Completed
NCT02278133 2017-10-09
Study of WNT974 in Combination With LGX818 and Cetuximab in Patients With BRAF-mutant Metastatic Colorectal Cancer (mCRC) and Wnt Pathway Mutations
Array BioPharma
Phase 1/2 Completed
NCT00704639 2017-07-12
Chemoradiation Treatment for Head and Neck Cancer
Trans Tasman Radiation Oncology Group
Phase 1/2 Completed
NCT00408499 2017-05-08
Erlotinib and Cetuximab in Treating Patients With Advanced Solid Tumors With Emphasis on Non-Small Cell Lung Cancer
University of California, Davis
Phase 1/2 Completed
NCT00216203 2016-09-29
Pemetrexed Plus Cetuximab in Patients With Recurrent Non Small Cell Lung Cancer
Hoosier Cancer Research Network
Phase 1/2 Completed
NCT01086267 2016-06-27
Safety and Efficacy Study of BMS-908662 Alone or in Combination With Cetuximab in Subjects With K-RAS or B-RAF Mutation Positive Advanced or Metastatic Colorectal Cancer
Bristol-Myers Squibb
Phase 1/2 Completed
NCT00544362 2016-05-30
Fluorouracil, Cisplatin, Cetuximab, and Radiation Therapy in Treating Patients With Esophageal Cancer That Can Be Removed by Surgery
Federation Francophone de Cancerologie Digestive
Phase 1/2 Completed
NCT01008475 2016-03-30
POSEIDON
Merck KGaA, Darmstadt, Germany
Phase 1/2 Completed
NCT00594984 2015-11-04
Phase I/II Combination With Irinotecan- Erbitux
Bristol-Myers Squibb
Phase 1/2 Completed
NCT00522665 2015-05-15
Phase I/Randomized Phase II Study of Second Line Therapy With Irinotecan + Cetuximab +/- RAD001 for Colorectal Cancer
Hoosier Cancer Research Network
Phase 1/2 Completed
NCT00778830 2015-05-14
APEC
Merck KGaA, Darmstadt, Germany
Phase 1/2 Completed
NCT00551421 2015-03-31
Pertuzumab and Cetuximab in Treating Patients With Previously Treated Locally Advanced or Metastatic Colorectal Cancer
National Cancer Institute (NCI)
Phase 1/2 Completed
NCT00815295 2014-12-08
Study of Sorafenib/Cetuximab in Head and Neck Cancer
Duke University
Phase 1/2 Completed
NCT01283334 2014-12-04
A Study of Carboplatin, Cetuximab and RAD001 in Advanced Head and Neck Cancer
Emory University
Phase 1/2 Completed
NCT00101348 2014-06-11
Erlotinib and Cetuximab With or Without Bevacizumab in Treating Patients With Metastatic or Unresectable Kidney, Colorectal, Head and Neck, Pancreatic, or Non-Small Cell Lung Cancer
National Cancer Institute (NCI)
Phase 1/2 Completed
NCT00705016 2014-04-30
ADVANTAGE
Merck KGaA, Darmstadt, Germany
Phase 1/2 Completed
NCT01712919 2014-03-24
Chemoradiation Plus Weekly c225 Against Locoregionally Advanced Nasopharyngeal Carcinoma (NPC)
Jiangsu Cancer Institute & Hospital
Phase 1/2 Completed
NCT00714649 2012-11-14
CHIRON
Cliniques universitaires Saint-Luc- Université Catholique de Louvain
Phase 1/2 Completed
NCT00445861 2012-06-11
Cetuximab, Docetaxel, Cisplatin, and Radiation Therapy in Treating Patients With Locally Advanced Esophageal Cancer That Can Be Removed by Surgery
Swiss Cancer Institute
Phase 1/2 Completed
NCT00034541 2010-04-09
Study of Cetuximab in Combination With Carboplatin-Paclitaxel in Non-Small Cell Lung Cancer
Eli Lilly and Company
Phase 1/2 Completed